NO306894B1 - Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet - Google Patents

Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet

Info

Publication number
NO306894B1
NO306894B1 NO952906A NO952906A NO306894B1 NO 306894 B1 NO306894 B1 NO 306894B1 NO 952906 A NO952906 A NO 952906A NO 952906 A NO952906 A NO 952906A NO 306894 B1 NO306894 B1 NO 306894B1
Authority
NO
Norway
Prior art keywords
pct
galanthamine
treatment
preparation
pharmaceutical formulation
Prior art date
Application number
NO952906A
Other languages
English (en)
Other versions
NO952906L (no
NO952906D0 (no
Inventor
Joachim Arnold Moormann
Original Assignee
Lohmann Therapie Syst Lts
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts, Hf Arzneimittelforsch Gmbh filed Critical Lohmann Therapie Syst Lts
Publication of NO952906L publication Critical patent/NO952906L/no
Publication of NO952906D0 publication Critical patent/NO952906D0/no
Publication of NO306894B1 publication Critical patent/NO306894B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO952906A 1993-01-23 1995-07-21 Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet NO306894B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4301782A DE4301782C1 (de) 1993-01-23 1993-01-23 Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
PCT/EP1994/000055 WO1994016708A1 (de) 1993-01-23 1994-01-10 Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit

Publications (3)

Publication Number Publication Date
NO952906L NO952906L (no) 1995-07-21
NO952906D0 NO952906D0 (no) 1995-07-21
NO306894B1 true NO306894B1 (no) 2000-01-10

Family

ID=6478780

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952906A NO306894B1 (no) 1993-01-23 1995-07-21 Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet

Country Status (23)

Country Link
US (1) US5643905A (no)
EP (1) EP0680326B1 (no)
JP (1) JP3511074B2 (no)
KR (1) KR100301547B1 (no)
AT (1) ATE146677T1 (no)
AU (1) AU685075B2 (no)
CZ (1) CZ284605B6 (no)
DE (2) DE4301782C1 (no)
DK (1) DK0680326T3 (no)
ES (1) ES2098920T3 (no)
GR (1) GR3022862T3 (no)
HR (1) HRP940029B1 (no)
HU (1) HU221159B1 (no)
IL (1) IL108234A (no)
MY (1) MY111260A (no)
NO (1) NO306894B1 (no)
NZ (1) NZ259858A (no)
PL (1) PL174812B1 (no)
SI (1) SI9400028A (no)
SK (1) SK282247B6 (no)
WO (1) WO1994016708A1 (no)
YU (1) YU48559B (no)
ZA (1) ZA94413B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
WO2000030446A1 (en) * 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
AP1414A (en) * 1998-12-24 2005-06-13 Janssen Pharmaceutica Nv Controlled release galantamine composition.
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
WO2001043697A2 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
DE10119862A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
ES2285233T3 (es) 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
CA2516618A1 (en) * 2003-02-27 2004-09-10 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Pharmaceutical composition for treatment of drug dependence
BG65658B1 (bg) * 2003-11-13 2009-05-29 "Софарма" Ад Комбиниран лекарствен продукт на основата на галантамин
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
WO2005115471A2 (en) * 2004-05-27 2005-12-08 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
CA2794333C (en) 2010-03-26 2019-02-12 Philip Morris Products S.A. Inhibition of sensory irritation during consumption of non-smokeable tobacco products
US8952038B2 (en) 2010-03-26 2015-02-10 Philip Morris Usa Inc. Inhibition of undesired sensory effects by the compound camphor
CN101829068A (zh) * 2010-05-06 2010-09-15 徐州市光合生物营养品有限公司 一种水溶性药物缓释片及其制备方法
BG66818B1 (bg) 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
US10335378B2 (en) 2013-03-15 2019-07-02 Altria Client Services Llc Inhibition of central nervous system effects from smoking and sensory effects from smoking
BG67408B1 (bg) 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3760805A (en) * 1971-01-13 1973-09-25 Alza Corp Osmotic dispenser with collapsible supply container
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4137300A (en) * 1976-08-20 1979-01-30 Ciba-Geigy Corporation Sustained action dosage forms
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3629304A1 (de) * 1986-08-28 1988-03-24 Lohmann Gmbh & Co Kg Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung
DE3843239C1 (no) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5312817A (en) * 1991-05-14 1994-05-17 Ernir Snorrason Treatment of fatigue syndrome
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans

Also Published As

Publication number Publication date
IL108234A (en) 1996-10-31
NO952906L (no) 1995-07-21
EP0680326B1 (de) 1996-12-27
HU9501964D0 (en) 1995-09-28
HU221159B1 (en) 2002-08-28
YU48559B (sh) 1998-11-05
PL174812B1 (pl) 1998-09-30
AU685075B2 (en) 1998-01-15
DK0680326T3 (da) 1997-06-23
ATE146677T1 (de) 1997-01-15
KR960700061A (ko) 1996-01-19
JPH08505633A (ja) 1996-06-18
SI9400028A (en) 1994-09-30
AU5881894A (en) 1994-08-15
SK89095A3 (en) 1996-05-08
ZA94413B (en) 1994-09-09
YU2494A (sh) 1997-01-08
HRP940029B1 (en) 2000-06-30
NZ259858A (en) 1997-03-24
DE59401401D1 (de) 1997-02-06
CZ184395A3 (en) 1996-02-14
KR100301547B1 (ko) 2001-10-22
PL309604A1 (en) 1995-10-30
SK282247B6 (sk) 2001-12-03
NO952906D0 (no) 1995-07-21
US5643905A (en) 1997-07-01
DE4301782C1 (de) 1994-08-25
IL108234A0 (en) 1994-04-12
ES2098920T3 (es) 1997-05-01
WO1994016708A1 (de) 1994-08-04
GR3022862T3 (en) 1997-06-30
CZ284605B6 (cs) 1999-01-13
HUT72670A (en) 1996-05-28
EP0680326A1 (de) 1995-11-08
JP3511074B2 (ja) 2004-03-29
HRP940029A2 (en) 1997-06-30
MY111260A (en) 1999-10-30

Similar Documents

Publication Publication Date Title
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
ATE195249T1 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
ATE202926T1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
MY124465A (en) Reduction of infarct volume using citicoline
WO2000048445A3 (de) Pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit
CA2350396A1 (en) A composition useful to treat periodontal disease
CA2120001A1 (en) Flavopereirine-based pharmaceutical composition and use thereof for treating hiv
GEP20043377B (en) Pharmaceutical Complex
AU3278800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence
ATE302010T1 (de) Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE234096T1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
ZA200100289B (en) Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees